Barrington G Burnett

List of Publications by Year in descending order

39 papers	3,571 citations	236925 25 h-index	302126 39 g-index
40 all docs	40 docs citations	40 times ranked	4978 citing authors

#	Article	IF	Citations
1	Viral mediated knockdown of <scp>GATA6</scp> in <scp>SMA iPSC</scp>â€derived astrocytes prevents motor neuron loss and microglial activation. Glia, 2022, 70, 989-1004.	4.9	17
2	A combinatorial approach increases SMN level in SMA model mice. Human Molecular Genetics, 2022, 31, 2989-3000.	2.9	2
3	Survival motor neuron protein deficiency alters microglia reactivity. Glia, 2022, , .	4.9	7
4	A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein. Cell Reports, 2021, 35, 109125.	6.4	6
5	Survival motor neuron deficiency slows myoblast fusion through reduced myomaker and myomixer expression. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1098-1116.	7.3	11
6	SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs. Skeletal Muscle, 2020, 10, 16.	4.2	9
7	Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy. Journal of Medicinal Chemistry, 2017, 60, 4594-4610.	6.4	13
8	The role of the immunoproteasome in interferon-Î³-mediated microglial activation. Scientific Reports, 2017, 7, 9365.	3.3	39
9	Socio-cultural adaptation and standardization of Dubois' five words testing in a population of normal subject in Mali, West Africa. ENeurologicalSci, 2016, 3, 60-63.	1.3	1
10	Genetics and genomic medicine in Mali: challenges and future perspectives. Molecular Genetics & Genomic Medicine, 2016, 4, 126-134.	1.2	8
11	MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy. Molecular Therapy, 2016, 24, 937-945.	8.2	29
12	CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiology of Disease, 2016, 88, 118-124.	4.4	35
13	Does the survival motor neuron copy number variation play a role in the onset and severity of sporadic amyotrophic lateral sclerosis in Malians?. ENeurologicalSci, 2016, 3, 17-20.	1.3	2
14	ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight, 2016, 1, e88427.	5.0	16
15	Survival motor neuron protein deficiency impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics. Human Molecular Genetics, 2014, 23, 4745-4757.	2.9	66
16	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	12.6	361
17	Genetics of low spinal muscular atrophy carrier frequency in subâ€Saharan Africa. Annals of Neurology, 2014, 75, 525-532.	5.3	31
18	Non-targeted Identification of Prions and Amyloid-forming Proteins from Yeast and Mammalian Cells. Journal of Biological Chemistry, 2013, 288, 27100-27111.	3.4	55

#	Article	IF	Citations
19	Hereditary Spastic Paraplegia Type 43 (SPG43) is Caused by Mutation inC19orf12. Human Mutation, 2013, 34, 1357-1360.	2.5	79
20	The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein. Molecular Biology of the Cell, 2013, 24, 1863-1871.	2.1	50
21	Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice. Human Molecular Genetics, 2012, 21, 4448-4459.	2.9	56
22	Neurogenic and Myogenic Contributions to Hereditary Motor Neuron Disease. Neurodegenerative Diseases, 2012, 9, 199-209.	1.4	5
23	Exome sequencing identifies a novel TRPV4 mutation in a CMT2C family. Neurology, 2012, 79, 192-194.	1.1	34
24	A candidate gene for autoimmune myasthenia gravis. Neurology, 2012, 79, 342-347.	1.1	21
25	Cowchock Syndrome Is Associated with a Mutation in Apoptosis-Inducing Factor. American Journal of Human Genetics, 2012, 91, 1095-1102.	6.2	134
26	Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Human Molecular Genetics, 2011, 20, 3667-3677.	2.9	64
27	Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C. Nature Genetics, 2010, 42, 170-174.	21.4	278
28	Impaired Synaptic Vesicle Release and Immaturity of Neuromuscular Junctions in Spinal Muscular Atrophy Mice. Journal of Neuroscience, 2009, 29, 842-851.	3.6	344
29	Regulation of SMN Protein Stability. Molecular and Cellular Biology, 2009, 29, 1107-1115.	2.3	234
30	Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Human Molecular Genetics, 2009, 18, 27-42.	2.9	171
31	Emerging treatment options for spinal muscular atrophy. Current Treatment Options in Neurology, 2009, 11, 90-101.	1.8	28
32	Targeting splicing in spinal muscular atrophy. Annals of Neurology, 2008, 63, 3-6.	5.3	5
33	Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition. Annals of Neurology, 2008, 64, 465-470.	5.3	133
34	Expression of expanded polyglutamine targets profilin for degradation and alters actin dynamics. Neurobiology of Disease, 2008, 30, 365-374.	4.4	37
35	Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Human Molecular Genetics, 2007, 16, 1593-1603.	2.9	137
36	Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. Journal of Clinical Investigation, 2007, 117, 659-671.	8.2	308

#	Article	IF	Citations
37	MicroRNA Pathways Modulate Polyglutamine-Induced Neurodegeneration. Molecular Cell, 2006, 24, 157-163.	9.7	240
38	The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4330-4335.	7.1	164
39	The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Human Molecular Genetics, 2003, 12, 3195-3205.	2.9	341